InspireMD, Inc. (NASDAQ:NSPR) Q4 2022 Earnings Call Transcript

Benjamin Haynor : Okay. And then on kind of maybe the new indication or new product front, I noticed in the 10-K, you mentioned MGuard EPS for acute stroke with tandem lesions. Can you tell us a little bit more there?

Marvin Slosman : Yes. I think a great opportunity for the CGuard stent because of the properties of having the MicroNet mesh as well as the design of our stent. We know that in about 25% of acute stroke cases, the carotids are involved. So we refer to that as tandem lesions. And so we’re looking at that as an indication opportunity that’s well suited for our stent and continue to work that in a parallel path to our approval under the current IDE as it we believe is best suited in that neuro application. And right now, there are no labels, specific labels or indications for tandem lesions stenting. So we continue to advance that process and are really encouraged by the stent’s ability to perform in that acute setting. Much more to come on that in the next few calls.

Benjamin Haynor : Okay. I’ll be on the lookout there. And then lastly for me. I appreciate the updates on C-Guardians. I was just curious what you’re seeing out of CREST-2? Any updates there?

Marvin Slosman : Yes. We’ve started enrollments with the CGuard and CREST-2 administratively. As you can imagine, there’s a lot that goes into making sure that all of the hospital systems are set and the stent is available and everything is done from a paperwork perspective. But having put that in the rearview mirror, we’re now beginning the enrollment process and are encouraged that we’ll see more and more enrollments with the CGuard. So we’re looking forward to an accelerated process there with CREST-2 as well.

Operator: Thank you. As there are no further questions at this time, I would like to turn the floor back over to Marvin Slosman for closing comments.

Marvin Slosman : Thank you. Again, we appreciate everybody attending the call, and we look forward to the balance of 2023 and a great reporting and continuing to progress in our advancement of CGuard stent system. Thank you for the call today.

Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.